What are the changes to the KwikPen and why?
The Mounjaro KwikPen device has been modified and includes visual and structural updates intended to address residual volume and indication of final dose delivery, indicating that the pen is ready to be discarded in accordance with instructions for use. The modified KwikPen works in the same way as the initial device.
The initial and modified Mounjaro KwikPens are both disposable multi-dose single-patient-use pre-filled pens, containing the volume of solution necessary for priming before each injection and the delivery of 4 fixed 0.6mL doses (one dose administered weekly).
We anticipate that the modified KwikPen will become available in the UK from April 2026.
The modified KwikPen works in the same way as the initial device, but there are a few visual and structural updates:
1. Plunger Position: The plunger sits further down in the cartridge when the pen is unused.
2. Extended Plunger: A new internal component has been added behind the plunger, extending its length. This is shown in the Mounjaro KwikPen Guide to Parts section in the Instructions For Use (IFU).
3. Remaining Medicine: After the fourth dose, the plunger will be near the end of the pen, clearly indicating the pen is ready to be discarded.
Mounjaro is a prescription-based weekly weight loss injection manufactured by Eli Lilly. Originally, it was approved for treating type 2 diabetes, but it has now become licensed for managing weight (BMI over 30) in adults. The Tirzepatide in Mounjaro curbs your hunger, creating satiety, which makes you eat less. For better results, Mounjaro for weight loss should be combined with a calorie-reduced diet and increased physical activity.
